Showing 3581-3590 of 7238 results for "".
- Delgocitinib Improves Patient-Reported Outcomes Across Chronic Hand Eczema Subtypeshttps://practicaldermatology.com/news/delgocitinib-improves-patient-reported-outcomes-across-chronic-hand-eczema-subtypes/2485611/Patient-reported outcome (PRO) data from the phase 3 DELTA 1 and DELTA 2 trials suggest that topical delgocitinib cream provides clinically meaningful symptom relief across major subtypes of chronic hand eczema (CHE), according to a poster from Robert Bissonnette,
- Nutrafol Launches Men 50+ Formula Targeting Age-Related Hair Thinninghttps://practicaldermatology.com/news/nutrafol-launches-men-50-formula-targeting-age-related-hair-thinning/2485568/Nutrafol announced an expansion of its men’s portfolio with the launch of Nutrafol Men 50+, a product designed specifically for men aged 50 years and older with thinning hair. According to the company, men entering their 50s ex
- Imagining a Better Future for Hidradenitis Suppurativahttps://practicaldermatology.com/news/imagining-a-better-future-for-hidradenitis-suppurativa/2485556/Hidradenitis suppurativa (HS) has long been misunderstood, underdiagnosed, and undertreated. However, at a recent panel discussion led by Vivian Shi, MD, at
- Empowering the HS Community Through Wellness, Nutrition, and Compassionhttps://practicaldermatology.com/news/empowering-the-hs-community-through-wellness-nutrition-and-compassion/2485555/Wellness goes beyond skin when it comes to managing hidradenitis suppurativa (HS). In an effort to spread awareness of that concept, HS Connect founder and CEO Brindley Brooks and COO Cristina Curp took the stage at
- Deuruxolitinib Produces Progressive Hair Regrowth in Severe Alopecia Areatahttps://practicaldermatology.com/news/deuruxolitinib-produces-progressive-hair-regrowth-in-severe-alopecia-areata/2485553/Deuruxolitinib produced progressive and clinically meaningful scalp hair regrowth in patients with severe alopecia areata, according to “Deuruxolitinib Improves Scalp Hair Regrowth Over Time in Patients With Severe Alopecia Areata,” a poster by Natasha A. Mesinkovska, MD, PhD, et al presented as
- Povorcitinib Improves Lesion Burden and Pain in Hidradenitis Suppurativahttps://practicaldermatology.com/news/povorcitinib-improves-lesion-burden-and-pain-in-hidradenitis-suppurativa/2485551/Oral povorcitinib produced early and sustained improvements in lesion burden and pain in patients with moderate-to-severe hidradenitis suppurativa (HS), according to “Effect of Povorcitinib on Hidradenitis Suppurativa Lesions Through 24 Weeks in STOP-HS Trials,” a poster by Jennifer L. Hsiao, MD,
- Intralesional Cemiplimab Shows High Pathologic Response in Early-Stage CSCChttps://practicaldermatology.com/news/intralesional-cemiplimab-shows-high-pathologic-response-in-early-stage-cscc/2485540/Low-dose intralesional cemiplimab produced high objective and pathologic response rates without treatment-limiting toxicity in patients with early-stage cutaneous squamous cell carcinoma (CSCC), according to “Intralesional Cemiplimab for Patients With Early-Stage Cutaneous Squamous Cell Carcinoma
- Review: Seven HS PROMs Meet COSMIN Standards for Clinical Usehttps://practicaldermatology.com/news/review-seven-hs-proms-meet-cosmin-standards-for-clinical-use/2485535/A new systematic review and meta-analysis found seven clinically useful tools for capturing and analyzing hidradenitis suppurativa (HS)–specific patient-reported outcome measures (PROMs). The review, which included 26 studies a
- Dr. Sheila Fallon Friedlander Highlights Pediatric Prevention, Guidelines, and Practical Care at Maui Derm Hawaiihttps://practicaldermatology.com/news/dr-sheila-fallon-friedlander-highlights-pediatric-prevention-guidelines-and-practical-care-at-maui-derm-hawaii/2485512/Giving clinicians tools they can use “in the here and now” was the theme as Sheila Fallon Friedlander, MD, presented on pediatric dermatology in one of the opening talks at Maui Derm Hawaii 2026. Dr. Friedlander covered prevention strategies, recent guideline updates, treatment safety (esp
- OX40‑Targeted Therapy Among Dr. Hensin Tsao’s Highlights at Maui Derm Hawaii 2026https://practicaldermatology.com/news/ox40targeted-therapy-among-dr-hensin-tsaos-highlights-at-maui-derm-hawaii-2026/2485510/A novel immune pathway that may redefine atopic dermatitis (AD) treatment paradigms was among the highlights presented by Hensin Tsao, MD, in his conference-opening presentation at Maui Derm Hawaii 2026. Melanoma immunotherapy and various other topics were covered, but perhaps the most pot